Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Ann Surg Oncol ; 30(13): 8335-8343, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-37679538

RESUMO

BACKGROUND: The 21-gene recurrence score (RS) is used to predict benefit from chemotherapy in hormone receptor (HR)-positive breast cancer with one to three positive lymph nodes. Prospective-retrospective studies have shown that the RS is prognostic for both systemic and locoregional recurrence in tamoxifen-treated patients. We aimed to assess whether RS could be utilized to predict a survival benefit from postmastectomy radiation therapy (PMRT). PATIENTS AND METHODS: The National Cancer Database (NCDB) was used to identify women ≤ 75 years of age with HR+, HER2-negative, T1-3, N1, M0 breast cancer who underwent mastectomy and axillary staging with available RS during the years 2010-2016. Kaplan-Meier and Cox proportional hazards models were used to identify association between treatment and overall survival (OS). Univariate and multivariate analyses were used to identify variables correlating with PMRT and OS. RESULTS: A total of 8907 patients were identified. Of the total, 3203 (36%) patients received adjuvant PMRT and 5704 (64%) did not. Across the entire cohort, 5-year OS was 97.5% for patients receiving PMRT and 96.8% for those who did not (P = 0.063). After adjusting for all covariates, in patients with RS ≤ 25, there was no statistically significant improvement in 5-year OS with the addition of adjuvant PMRT (97.5% versus 98.1% P = 0.093). Moreover, no survival benefit was seen with axillary node dissection (P = 0.58) or with the addition of chemotherapy (P = 0.312). CONCLUSIONS: In our cohort of patients with one to three positive nodes and a RS ≤ 25, omission of post-mastectomy radiation therapy had no impact on OS. Our results suggest that RS may be utilized in the individualized decision making on PMRT.


Assuntos
Neoplasias da Mama , Humanos , Feminino , Recém-Nascido , Neoplasias da Mama/cirurgia , Mastectomia , Estudos Retrospectivos , Estudos Prospectivos , Linfonodos/patologia , Radioterapia Adjuvante/métodos , Estadiamento de Neoplasias , Recidiva Local de Neoplasia/patologia
2.
Harefuah ; 158(4): 233-236, 2019 Apr.
Artigo em Hebraico | MEDLINE | ID: mdl-31032554

RESUMO

INTRODUCTION: The clinicopathologic characterization of tumoral intra-epithelial neoplasms of the gallbladder is fairly limited compared to that of similar tumors of the pancreatobiliary system. Until recently, pre-malignant lesions of the gallbladder were mostly reported as adenomas, which were microscopic and therefore regarded as benign and clinically inconsequential, whereas papillary lesions have been largely regarded as a papillary subtype of gallbladder invasive adenocarcinoma. In an attempt to create a unified terminology for these tumors, the term Intracholecystic papillary-tubular neoplasm (ICPN) was proposed to include all exophytic intra-epithelial tumors of the gallbladder measuring ≥1 cm under one category. A few studies which have retrospectively analyzed tumors fulfilling this category found them to be remarkable analogous to the more well-characterized intra-epithelial tumors of the pancreato-biliary system such as IPMN of the pancreas and IPNB of the bile ducts and as such they also represent an 'adenoma-carcinoma' sequence in the gallbladder. Since then a number of case series have been published which attempted to characterize the clinical and pathological features of these tumors and their relationship with invasive carcinoma. In this paper we report three cases of ICPN which represent different stages of the 'adenoma-carcinoma' sequence.


Assuntos
Adenocarcinoma , Adenoma , Neoplasias da Vesícula Biliar , Adenocarcinoma/patologia , Adenoma/patologia , Neoplasias da Vesícula Biliar/patologia , Humanos , Invasividade Neoplásica , Estudos Retrospectivos
3.
Harefuah ; 153(12): 727-30, 752, 2014 Dec.
Artigo em Hebraico | MEDLINE | ID: mdl-25654914

RESUMO

INTRODUCTION: In recent years, laparoscopic adrenalectomy has become the procedure of choice for small and benign adrenal lesions. With the experience gained in the laparoscopic approach, many surgeons have expanded the range of indications for laparoscopic adrenalectomy and nowadays, this approach is used for large adrenal lesions and in lesions suspicious for malignancy. However, great controversy still exists regarding the oncological safety of this approach and therefore, some surgeons still prefer using the open technique. PURPOSE: To assess the outcome and the oncological safety of Laparoscopic adrenalectomy of large adrenal lesions. METHODS: A retrospective analysis was conducted of prospectively collected data of all consecutive patients who underwent laparoscopic adrenatectomy in our department for adrenal lesions of 6 cm or larger during the years 1995-2014. RESULTS: A total of 50 patients, out of 230 who underwent laparoscopic adrenalectomy in our department, were included in the study. The main indications for surgery were pheochromocytoma, non-functional lesions and Cushing's syndrome. The surgical approach in all cases was the lateral transperitoneal approach. The final histopathological diagnoses in the majority of patients were adenoma and pheochromocytoma. Three patients were diagnosed with adrenocortical carcinoma. During a follow-up period of up to 5-years, no Local or distant recurrences were found. CONCLUSIONS: The laparoscopic approach for removal of adrenal lesions Larger than 6 cm is safe in respect of intra- and peri-operative morbidity as well as oncological safety. The true incidence of malignancy in large adrenal Lesions appears to be lower than that reputed in the Literature thus far. In high-volume centers the laparoscopic approach should be attempted for large adrenal lesions.


Assuntos
Neoplasias das Glândulas Suprarrenais/cirurgia , Glândulas Suprarrenais/patologia , Adrenalectomia , Síndrome de Cushing/cirurgia , Laparoscopia , Feocromocitoma/cirurgia , Complicações Pós-Operatórias/prevenção & controle , Neoplasias das Glândulas Suprarrenais/patologia , Adrenalectomia/efeitos adversos , Adrenalectomia/métodos , Pesquisa Comparativa da Efetividade , Síndrome de Cushing/diagnóstico , Feminino , Humanos , Israel , Laparoscopia/efeitos adversos , Laparoscopia/métodos , Masculino , Pessoa de Meia-Idade , Metástase Neoplásica/prevenção & controle , Recidiva Local de Neoplasia/prevenção & controle , Feocromocitoma/patologia , Reprodutibilidade dos Testes , Estudos Retrospectivos , Resultado do Tratamento
4.
Surgery ; 172(1): 25-30, 2022 07.
Artigo em Inglês | MEDLINE | ID: mdl-35241302

RESUMO

BACKGROUND: Racial disparities in accessing postmastectomy breast reconstruction persist despite expansion of insurance coverage. An updated examination with a broad assessment of mediating factors in a "majority minority" community is needed. METHODS: Data were collected on all patients undergoing mastectomy for breast cancer from 2011 to 2019 in a private academic center and adjacent safety-net hospital. Multivariable logistic regression was used to assess the effect of race on postmastectomy breast reconstruction, controlling for predetermined potentially mediating and confounding variables. RESULTS: Of 1,554 patients, 63.8% (n = 203) of non-Hispanic White, 33.4% (n = 102) of Black, and 47.9% (n = 438) of Hispanic patients underwent postmastectomy breast reconstruction. Multivariable logistic regression showed that Black patients (odds ratio [OR] 3.6, 95% confidence internal [CI]: 2.2-5.9; P < .0001) undergo significantly less postmastectomy breast reconstruction than White patients. Age, insurance status, stage, and hospital type mediated this relationship. CONCLUSION: Black patients have substantially reduced rates of postmastectomy breast reconstruction compared with White patients, which is mediated by socioeconomic factors.


Assuntos
Neoplasias da Mama , Mamoplastia , Neoplasias da Mama/cirurgia , Feminino , Disparidades em Assistência à Saúde , Humanos , Cobertura do Seguro , Mastectomia
5.
J Immunol ; 182(4): 2221-30, 2009 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-19201876

RESUMO

The in vitro elimination of virus-infected and tumor cells by NK cells is regulated by a balance between signals conveyed via specific inhibitory and activating receptors. Whether NK cells and specifically the NK-activating receptor NKp46 (NCR1 in mice) are directly involved in tumor eradication in vivo is still largely unknown. Since the NKp46/NCR1 tumor ligands have not been identified yet, we use a screening technique to identify functional ligands for NKp46/NCR1 which is based on a cell reporter assay and discover a NCR1 ligand in the PD1.6 lymphoma line. To study whether NKp46/NCR1 is important for the eradication of PD1.6 lymphoma in vivo, we used the Ncr1 knockout Ncr1(gfp/gfp) mice generated by our group. Strikingly, all Ncr1 knockout mice developed growing PD1.6 tumors, whereas initial tumor growth was observed in the wild-type mice and tumors were completely rejected as time progressed. The growth of other lymphoma cell lines such as B10 and EL4 was equivalent between the Ncr1 knockout and wild-type mice. Finally, we show that PD1.6 lymphoma cells are less killed both in vitro and in vivo in the absence of NKp46/NCR1. Our results therefore reveal a crucial role for NKp46/NCR1 in the in vivo eradication of some lymphoma cells.


Assuntos
Antígenos Ly/imunologia , Citotoxicidade Imunológica/imunologia , Células Matadoras Naturais/imunologia , Linfoma/imunologia , Receptor 1 Desencadeador da Citotoxicidade Natural/imunologia , Animais , Antígenos Ly/genética , Citometria de Fluxo , Técnicas In Vitro , Linfoma/genética , Camundongos , Camundongos Knockout , Receptor 1 Desencadeador da Citotoxicidade Natural/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA